Nasdaq · CIK 0001875091
NRSN NeuroSense Therapeutics Ltd.
Insider trading from SEC Form 4. Last filing Jun 17, 2026. Close $3.66 on Oct 9, 2026, +1002% from the 52-week low and -65% from the high.
In brief
NeuroSense Therapeutics Ltd. (NRSN) has 5 SEC Form 4 filings on file from 4 insiders, the latest filed on Jun 17, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at NRSN. The newest: Alon Ben-Noon (Chief Executive Officer) bought $200k of stock on Jun 16, 2026, filed Jun 17, 2026, scored 66 (notable). 2 insiders bought within 14 days of each other around Jun 16, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NeuroSense Therapeutics Ltd., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 66Notable | Alon Ben-Noon Chief Executive Officer buy | $200k 250,000 shares | +6% | +2% from low-71% from high | |
| 63Notable | Or Eisenberg Chief Financial Officer buy | $200k 250,000 shares | +20% | +2% from low-71% from high |
Transactions
Every row filed, 5 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Alon Ben-Noon Chief Executive Officer | POpen-market purchase Ordinary Shares | +250,000 | $0.80 | $200k | 4,534,233 | Jun 17, 2026 |
| Jun 16, 2026 | Or Eisenberg Chief Financial Officer | POpen-market purchase Ordinary Shares | +250,000 | $0.80 | $200k | 1,504,050 | Jun 17, 2026 |
| Mar 26, 2026 | Or Eisenberg Chief Financial Officer | AGrant or award Ordinary Shares | +200,000 | $0.00 | $0 | 1,254,050 | Apr 1, 2026 |
| Mar 26, 2026 | Hagit Binder General Manager | AGrant or award Ordinary Shares | +200,000 | $0.00 | $0 | 521,806 | Mar 30, 2026 |
| Mar 26, 2026 | Niva Russek-Blum Chief Technology Officer | AGrant or award Ordinary Shares | +200,000 | $0.00 | $0 | 467,953 | Mar 30, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Alon Ben-NoonChief Executive Officer
- Hagit BinderGeneral Manager
- Or EisenbergChief Financial Officer
- Niva Russek-BlumChief Technology Officer
Questions about NRSN
Answered from the filings on this page, as of the latest one.
Are insiders buying NRSN?
No. In the last 90 days no insider at NeuroSense Therapeutics Ltd. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NRSN on the open market?
Alon Ben-Noon (Chief Executive Officer) bought $200k of NRSN on Jun 16, 2026 and filed the Form 4 on Jun 17, 2026. InsiderTell scored 66 (notable), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at NeuroSense Therapeutics Ltd.?
4 people have filed a Form 4 at NeuroSense Therapeutics Ltd., among them Alon Ben-Noon (Chief Executive Officer), Hagit Binder (General Manager), Or Eisenberg (Chief Financial Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.